Famicord Ag · XETR:V3V
Famicord — Vita 34 — Investor Presentation (November 2022)
18 slides from Famicord's investor presentation, November 2022
Slide 1: Vita 34 – More than the Cell Bank
VITA 34 – MORE THAN THE CELL BANK INVESTOR PRESENTATION, NOVEMBER 2022 INVESTOR PRESENTATION - NOVEMBER 2022 1 1
Slide 2: New Enhanced Management Board - Stronger Focus on Sales & Marketing
NEW ENHANCED MANAGEMENT BOARD - STRONGER FOCUS ON SALES & MARKETING Tomasz Baran (CCO) Jakub Baran (CEO) Dirk Plaga (CFO) § In the company since 2010 § Co-founder, in the company since 2005 § Joined Board in August 2022 § 10+ years experience at Big Pharma § 10+ years experience in Sales & IT at § E
Slide 3: The New Vita 34 at a Glance
THE NEW VITA 34 AT A GLANCE ü No. 1 in Europe, No. 3 worldwide ü Drug Manufacturing & Related ü 850+ k biological samples stored § Experimental therapies + storage for ~300k ex-Cryo-Save clients § Multiple CMO contracts ü ~ 95 % of Group revenues § Medical services § ~ 5 % of Group revenues Leading
Slide 4: European Market Coverage of the Combined Entity
EUROPEAN MARKET COVERAGE OF THE COMBINED ENTITY ~80% ü Clearly dominant European market leader market coverage in Europe ü Strong cash flow from operations as basis for accelerated organic & inorganic growth ü Finalization of industry consolidation in Europe as clear strategic target within max. 5 y
Slide 5: Family Banking Service Before and After Merger with Famicord
FAMILY BANKING SERVICE BEFORE… AND AFTER MERGER WITH FAMICORD Present process from customer acquisition to storage, adaptable also for new product segments NEW 1. 2. 3. 4. 5. 6. 7. Information Order via Collection in Shipping to Processing Storage in Possible via doctors, Internet, partner Vita 34 i
Slide 6: General Business Model – Critical Success Factors
GENERAL BUSINESS MODEL – CRITICAL SUCCESS FACTORS High Market Proven Coverage Technology ü High market coverage of clinics ü High cell yield (e.g. Germany ~82% of maternity clinics) ü Autologous and allogenic use ü Market partnerships provide further upside ü ~5000 samples used for various applicati
Slide 7: 2022 / 2023 Focus Points – Post Merger Key Priorities
2022 / 2023 FOCUS POINTS – POST MERGER KEY PRIORITIES 01 02 03 04 05 Priority Priority Priority Priority Priority New Strategy Return to Growth Post Merger Unified Group Financing of Formulation Path in Integration Reporting FamiCordTx Key Markets & IT System beyond 2023 INVESTOR PRESENTATION - NOVE
Slide 8: New Storages, Recurring Revenues & High Impact of Contract Renewals
NEW STORAGES, RECURRING REVENUES & HIGH IMPACT OF CONTRACT RENEWALS Simplified illustration of revenue streams ü About 59 % of customers choose up-front payment (à one-time cash revenue) vs. 41 % yearly payment contracts (à recurring cash Revenues Start of revenue) contract renewal phase ü Up-front
Slide 9: Development of Subscription Revenues (Pro-forma Data)
DEVELOPMENT OF SUBSCRIPTION REVENUES (PRO-FORMA DATA) Number of B2C clients in Invoiced net annual storage fee annual subscription model intheB2C segment1) 230 in k units in EURm 210,7 199,2 15,7 187,3 14,0 174,5 12,9 Subscription / Prepayment 10,4 11,6 139,1 Client split in 2021 8,2 in k units 2016
Slide 10: Rapidly Growing Market of Cell & Gene Therapies
RAPIDLY GROWING MARKET OF CELL & GENE THERAPIES $14bn funds raised by the CGT companies in 1H2021 only, ~75% of the last year record of $19.9bn § CGTs account for approx. 1% of therapies approved in Large capital development for CAR-T therapies major markets, but as many as ~12% of pipeline clinical
Slide 11: Group R&D Projects I
GROUP R&D PROJECTS I Project Description Stroke Therapy ü Bone Marrow CD34+ cells in ischemic stroke patients. ü Clinical trial Approved by National Ethics Committee for Clinical Research, waiting for National Authority of Medicines and Health Products approval. ü No additional costs until the regul
Slide 12: Group R&D Projects II
GROUP R&D PROJECTS II Project Description Circulate ü UC MSC for cardiac diseases (Chronic Ischemic Heart Failure, Critical Limb Ischemia, Acute Myocardial Inf.) (Consortium) ü Project finished: no follow-ups in terms of ATMP development ü After further analysis, project is currently on hold as inve
Slide 13: Efficient & Proven Core Product FCTX-CL19-1
EFFICIENT & PROVEN CORE PRODUCT FCTX-CL19-1 US-licensed technology for fast development of the first product FamiCordTx Mechanism of action antiCD19 CAR structure § A unique construct with patented unique anti- scFV CD19 antibody sequence with a CD19 system of intracellular domains antibody with pro
Slide 14: R&D CAR-T Pipeline Summary
R&D CAR-T PIPELINE SUMMARY Pre-tested anti-CD19 CART with faster clinical path; allogenic and solid tumor products development pipeline already on board Field Candidate Init. Research Adv. Research Preclinical Bioethical Clinical Phase I Committee DLBCL Anti-CD 19 1 CAR Non-canon. Application Cord b
Slide 15: Key Group Financials 9M 2022
KEY GROUP FINANCIALS 9M 2022 in EUR ´000 Q3 Q3 9M 9M 9M Key Financials 2022 2021* 2022 2021* ∆ Revenues 18,655 5,646 50,764 16,111 215.1% Gross profit 5,987 3,404 13,409 9,419 42.4% EBITDA 1,008 1,486 - 1,606 3,137 -151.2% EBITDA margin [%] 5.4% 26.3% -3.2% 19.5% EBIT - 1,111 828 - 7,976 954 -936.0%
Slide 16: Guidance Transition Year 2022
GUIDANCE TRANSITION YEAR 2022 GROUP REVENUES GROUP EBITDA EUR 65 – 72 m EUR -6 – -3 m § Revenues from core business under pressure due to weakening of economic environment § Q3 2022 burdened by effects of harmonization reg. IFRS 15 for the last time. § Further investments in new expanding business a
Slide 17: Share Price Development Mostly in Line with Market Development
SHARE PRICE DEVELOPMENT MOSTLY IN LINE WITH MARKET DEVELOPMENT 18,0 0 SDAX (ind .) Vita 34 AG (XETRA) 16,00 14,00 12,00 10,00 8,00 6,0 0 Jan. 21 Ap r. 21 Jul. 21 Okt. 21 Jan. 22 Ap r. 22 Jul. 22 Okt. 22 Key data Equity Research ISIN DE0007238008 Montega Research, Tim Kruse HOLD, PT 10.00 Segment Pri
Slide 18: Contact: Vita 34 AG
Contact: Vita 34 AG Ingo Middelmenne Investor Relations Perlickstraße 5 04103 Leipzig Tel. +49 341 48792 7574 Fax +49 341 48792 39 E-Mail: ingo.middelmenne@vita34.de www.vita34.de INVESTOR PRESENTATION - NOVEMBER 2022 18 18